Want to see AU:DXB full AI Analyst Report?
DXB Stock Chart & Stats
AU$0.29
>-AU$0.01(-2.00%)
At close: 4:00 PM EDT
AU$0.29
>-AU$0.01(-2.00%)
Day’s Range― - ―
52-Week RangeAU$0.16 - AU$0.67
Previous CloseN/A
Volume265.68K
Average Volume (3M)1.07M
Market Cap
AU$147.10M
Enterprise ValueAU$107.16
Total Cash (Recent Filing)AU$16.15M
Total Debt (Recent Filing)AU$232.09K
Price to Earnings (P/E)―
Beta2.59
Next Earnings
Mar 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding600,396,800
10 Day Avg. Volume932,160
30 Day Avg. Volume1,067,999
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-8.34
Price to Sales (P/S)28.29
P/FCF Ratio-2.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$9.00M
Bulls Say, Bears Say
Bulls Say
Low LeverageGenerally low debt reduces the burden of interest and principal payments, preserving financial flexibility compared with a highly leveraged biotechnology company. This can help Dimerix direct more resources toward clinical development and partnerships, although it does not remove broader funding needs.
High Gross Profit ProfileHigh gross profit relative to revenue indicates that the underlying economics of reported revenue can be attractive before operating costs. If revenue becomes more consistent, this margin profile could provide operating leverage as development activity matures and fixed costs are spread across a larger base.
Focused Lead ProgramA focused lead program gives Dimerix a clear strategic direction around DMX-200 and unmet renal indications rather than an unfocused collection of projects. Clinical progress or a successful partner could create milestone, licensing, royalty, or commercial opportunities over the medium term.
Bears Say
Persistent Deep LossesPersistent operating and net losses show that Dimerix has not yet reached a self-sustaining commercial earnings model. Continued losses can constrain investment capacity, increase dependence on financing or partners, and make future profitability dependent on successful clinical and commercial execution.
Heavy Cash BurnNegative operating and free cash flow in most periods indicate that the business is consuming cash rather than funding development internally. The sharp 2026 burn increases the likelihood of ongoing capital needs, which may dilute shareholders or force less favorable financing if conditions tighten.
Negative EquityNegative equity is a significant balance-sheet weakness because it reflects a capital base eroded by accumulated losses or financing effects. Even with low debt, this reduces financial resilience, limits flexibility in funding clinical programs, and heightens reliance on external capital or partnering proceeds.
Dimerix Limited News
DXB FAQ
What was Dimerix Limited’s price range in the past 12 months?
Dimerix Limited lowest share price was AU$0.16 and its highest was AU$0.67 in the past 12 months.
What is Dimerix Limited’s market cap?
Dimerix Limited’s market cap is AU$147.10M.
When is Dimerix Limited’s upcoming earnings report date?
Dimerix Limited’s upcoming earnings report date is Mar 01, 2027 which is in 160 days.
How were Dimerix Limited’s earnings last quarter?
Dimerix Limited released its earnings results on Aug 26, 2026. The company reported -AU$0.023 earnings per share for the quarter.
Is Dimerix Limited overvalued?
According to Wall Street analysts Dimerix Limited’s price is currently Overvalued.
Does Dimerix Limited pay dividends?
Dimerix Limited does not currently pay dividends.
What is Dimerix Limited’s EPS estimate?
Dimerix Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dimerix Limited have?
Dimerix Limited has 600,396,800 shares outstanding.
What happened to Dimerix Limited’s price movement after its last earnings report?
Dimerix Limited reported an EPS of -AU$0.023 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Dimerix Limited?
Currently, no hedge funds are holding shares in AU:DXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dimerix Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:DXB Sentiment 91%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-35.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Dimerix Limited
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.
Technical Analysis
Actinogen Medical
―
Alterity Therapeutics
―
Immutep Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―